To be fair you have a point, but the worth the investment or not depends on risk tolerance. Would I bet the house.... no. Enough to hurt but a win will change my retirement plans.....yes.
The critism has foundation, but realistically other companies take as long. So yeah cut the PR speel
and stick to facts.
Avacta and to some extent AIM is like public VC calls. High risk, high gain. The main market has sold me lower risk, more mature/experienced stocks/ceos
VC not unusual to provide stock options for workers who are likely working their nads off to realize your investment.
search vox paul hill, and goto home page
Why doesn’t he buy shares? No cash or not allowed?
more likely the usage is spun off. Avacta don't have a global sales and distribution line, so the value is in the license rather than the "business".
I doubt the company per se would be split.
good find, thanks
also wants it hit a certain market cap, some new players enter. That should hopefully also mean some upward pressure.
The revenue for Covid, awesome, but then think about the use of antibodies in diagnostics. They are difficult to produce, hard to handle, big etc etc. Covid is baptism of fire but also means a huge reference case for other conditions. That medium and long term story is a strong force. 1 year windfall revenue nice, might be longer, but a new tool for a huge list of diagnostics tests will attract bigger fish.
Interesting thread. Thanks all.
Whilst the opportunity isn’t concrete, nice to see the scope of opportunity. Takes bandwidth thou and expertise.
Maybe TT requires supply chain to be secured and is waiting for QA certification. Mologic somehow can make ce marked tests without Avacta having a cert.
Have to admit I have no idea how it works in pharm.
anyone have any idea. Could Mologic make own Affimers under own cert with Avacta permission?
Just wild guesses in my part, but interesting TT not complete.
Interesting, thanks for posting
Supply Elisa based tests.
But it says Avacta developed Affimers for targets.
Guess we are wondering if this includes Covid. Guess Biokit want to make own splash later.
I kinda want it to be more than covid,
Avacta not going down route of supplying own tests. Good move at this stage, marketing, sales, distribution all take people. Hopefully see a few more jump on board, now Affimers are proving themselves.
made me smile almost as much as the RNS
@risk. Thanks
For some reason (blind optimism about retiring soon), I though Mologic in March with Avacta ce end.
My bad.
My bill? .... bike?
End of March for CE is cool and I couldn’t less how it’s achieved.
Rather a company gives estimates and accept that are only that. It’s better than zero info.
just it was interesting to see a date change tagged on the end of some good news.I would have thought affirmed affinity for the variants named has been known for a while.
But I guess we can wait to see when Avacta ce mark and Mologic marks are issued. My bet Mologic one not before end March.
Good news.
One odd thing was end of March for CE. That’s was the date for Avacta own CE once quality certifications as approved. Mologic CE mark is meant to be before then. CE mark by end of March great but once again some fuzzy talk. If the date has slipped say so.
made turning up today worthwhile !
Guardian article about Germany and vaccines mention Germany expecting rapid antigen tests to be available soon. Some delay, from end of March, but bloody great there is expectation. It was a question to German health minister Spahn.
If Avacta doesn’t have certification yet, and Mologic are releasing a test before they do, does it mean the mologic are making the Affimers? Those are then covered by their own process.
Or can mologic use Affimers that are produced by uncertified supply, so long as they have a quality assurance test method ?
Either way it’s shows how rapid expansion third parties can be achieved once others trust the test/Avacta come to market first. Flood gates would open really quickly. I wonder how many are cooking up something behind the scenes just waiting for the CV to be over.
https://www.theguardian.com/world/2021/feb/23/new-covid-test-delivers-results-three-times-faster-than-lateral-flow?CMP=Share_iOSApp_Other
I presume antibody particles could be replaced with Affimers. Anyone know if Avacta have researched this tech and if so are they looking deeper?